Keyword: Kymriah (tisagenlecleucel)
Takeda releases first post-Shire guidance; Indian generics makers are named in a price-fixing suit; Daiichi's quizartinib fails at FDA.
The price, though a discount from its U.S. sticker, makes Kymriah the most expensive treatment offered on the Japanese public insurance system.
With FDA approval of Zolgensma expected soon, Novartis CEO Vasant Narasimhan is confident that the company's manufacturing network will meet demand.
With Yescarta on the market and other CAR-Ts on their way, Gilead’s Kite Pharma planted the flag for another manufacturing site.
Novartis' AveXis is buying a former AstraZeneca production site in Colorado as part of the biotech's rapid manufacturing buildout.
To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.
French biotech Cellectis is building facilities in Paris and the U.S. to produce allogeneic CAR-T treatments.
Pharmas often face scrutiny on price hikes for old drugs, but now investors are asking Novartis about high prices for groundbreaking new drugs.
Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
Two senators have introduced a bill designed to encourage deals that would allow insurers to spread payments for expensive therapies over time.